Adocia: New phase Ib start with BC lispro

BUY, Fair Value EUR113 (+52%)
News published on September Wednesday 30, 2015
Share on

A new phase Ib study is starting with BC lispro in type II diabetes. Lilly, whose Diabetes franchise has strengthened a lot with Trulicity and Jardiance recently, shows strong commitment to BC lispro. It is still the prime asset of Adocia. We still expect a phase III start in H1 2016.


For more information, please contact marketing@bryangarnier.com 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities